Sex Differences in Immunology: More Severe Development of Experimental Pulmonary Hypertension in Male Rats Exposed to Vascular Endothelial Growth Factor Receptor Blockade
Standard
Sex Differences in Immunology: More Severe Development of Experimental Pulmonary Hypertension in Male Rats Exposed to Vascular Endothelial Growth Factor Receptor Blockade. / Guihaire, Julien; Deuse, Tobias; Wang, Dong; Fadel, Elie; Reichenspurner, Hermann; Schrepfer, Sonja.
In: BIOMED RES INT , Vol. 2015, 2015, p. 765292.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Sex Differences in Immunology: More Severe Development of Experimental Pulmonary Hypertension in Male Rats Exposed to Vascular Endothelial Growth Factor Receptor Blockade
AU - Guihaire, Julien
AU - Deuse, Tobias
AU - Wang, Dong
AU - Fadel, Elie
AU - Reichenspurner, Hermann
AU - Schrepfer, Sonja
PY - 2015
Y1 - 2015
N2 - BACKGROUND: The epidemiology of pulmonary hypertension (PH) is characterized by a female preponderance, whereas males share higher severity of the disease.OBJECTIVE: To compare the severity of experimental PH between male and female athymic rats.METHODS: PH was induced in 11 male and 11 female athymic rats (resp., SU_M and SU_F groups) using an inhibitor of VEGF-receptors I and II, semaxanib (40 mg/kg). After 28 days, right ventricular (RV) remodeling, systolic function, and hemodynamics were measured using echocardiography and a pressure-volume admittance catheter. Morphometric analyses of lung vasculature and RV myocardium were performed.RESULTS: Four weeks after semaxanib injection, RV end-systolic pressure was higher in SU_M than in SU_F. Males developed marked RV enlargement and systolic dysfunction compared to females. Impairment of RV-PA coupling efficiency was observed only in SU_M. The smooth muscle cells of the pulmonary arteries switched from a contractile state to a dedifferentiated state only in males.CONCLUSIONS: Female athymic rats were protected against the development of severe PH. RV-PA coupling was preserved in females through limitation of pulmonary artery muscularization. Control of smooth muscle cells plasticity may be a promising therapeutic approach to reverse established vascular remodeling in PH patients.
AB - BACKGROUND: The epidemiology of pulmonary hypertension (PH) is characterized by a female preponderance, whereas males share higher severity of the disease.OBJECTIVE: To compare the severity of experimental PH between male and female athymic rats.METHODS: PH was induced in 11 male and 11 female athymic rats (resp., SU_M and SU_F groups) using an inhibitor of VEGF-receptors I and II, semaxanib (40 mg/kg). After 28 days, right ventricular (RV) remodeling, systolic function, and hemodynamics were measured using echocardiography and a pressure-volume admittance catheter. Morphometric analyses of lung vasculature and RV myocardium were performed.RESULTS: Four weeks after semaxanib injection, RV end-systolic pressure was higher in SU_M than in SU_F. Males developed marked RV enlargement and systolic dysfunction compared to females. Impairment of RV-PA coupling efficiency was observed only in SU_M. The smooth muscle cells of the pulmonary arteries switched from a contractile state to a dedifferentiated state only in males.CONCLUSIONS: Female athymic rats were protected against the development of severe PH. RV-PA coupling was preserved in females through limitation of pulmonary artery muscularization. Control of smooth muscle cells plasticity may be a promising therapeutic approach to reverse established vascular remodeling in PH patients.
KW - Animals
KW - Echo-Planar Imaging
KW - Female
KW - Fluorescent Antibody Technique
KW - Heart Ventricles/pathology
KW - Hemodynamics
KW - Hypertension, Pulmonary/immunology
KW - Male
KW - Pulmonary Artery/pathology
KW - Rats
KW - Receptors, Vascular Endothelial Growth Factor/antagonists & inhibitors
KW - Sex Characteristics
U2 - 10.1155/2015/765292
DO - 10.1155/2015/765292
M3 - SCORING: Journal article
C2 - 26421302
VL - 2015
SP - 765292
JO - BIOMED RES INT
JF - BIOMED RES INT
SN - 2314-6133
ER -